Strategies for Prevention and Treatment of Recurrent C. difficile Infection
In this educational activity, experts will apply concepts of epidemiology, pharmacology, immunology, and microbiome science to describe the sequence of events that place patients at high risk for recurrent CDI. Attendees will be able to formulate cost-effective treatment plans that optimize therapy and provide a rational anti-CDI recurrence treatment strategy. The current and near future therapeutic targets to prevent CDI recurrence will also be highlighted.
Agenda
Welcome and Introductions
Kevin W. Garey Pharm.D., M.S., FASHP, Activity Chair
Epidemiology, pharmacology, immunology, and microbiome science of Clostridioides difficile infection: Focus on prevention of CDI recurrence
Pablo C. Okhuysen, M.D., FACP, FIDSA
Treatment plan for CDI based on underlying risk of recurrence
Kevin W. Garey Pharm.D., M.S., FASHP
The Great Debate: Is the future of CDI treatment and prevention focused on microbiome restoration supplements, antibiotics, or something else?
Kevin W. Garey Pharm.D., M.S., FASHP and Pablo C. Okhuysen, M.D., FACP, FIDSA
Faculty Discussion and Audience Questions
Learning Objectives
- Apply concepts of epidemiology, pharmacology, immunology, and microbiome science to stratify patients at risk of developing recurrent Clostridioides difficile infection (CDI).
- Develop anti-recurrence strategies for treating patients with recurrent CDI.
- Formulate a treatment plan for CDI based on underlying risk of recurrence.
- Investigate current and future therapeutic targets to prevent recurrent CDI.
Target Audience
This activity was planned to meet the educational needs of physicians, pharmacists, physician assistants, and nurse practitioners involved in the treatment of patients with Clostridioides difficile infection.
Format
This online activity consists of slide presentations, active learning, an assessment, and evaluation. View the system requirements.
Disclosures
In accordance with ACCME and ACPE Standards for Commercial Support, ASHP policy requires that all faculty, planners, reviewers, staff, and others in a position to control the content of this presentation disclose their financial relationships.
In this activity, only the individuals below have disclosed a relevant financial relationship. No other persons associated with this presentation have disclosed any relevant financial relationships.
Kevin W. Garey, Pharm.D., M.S., FASHP
- Merck: Principal investigator
Pablo C. Okhuysen, M.D., FACP, FIDSA
- Summit Therapeutics: Principal Investigator
- Pfizer: Consultant
- Merck: Consultant
- Jaguar Health, Inc.: Consultant
- Singulex: Consultant
Claim CE Within 60 Days
Participants should claim CE credit for this home-study activity only if they have not claimed credit for the live activity.
To receive CE credit, complete the steps below within 60 days of completing the activity.
- View entire presentation and answer all polling questions.
- Click "Complete Activity" on the last slide to complete the assessment and evaluation.
- Verify credits were successfully transferred to CPE Monitor before the ACPE 60-day deadline by checking your NABP eProfile account.
After the 60-day deadline, ASHP will no longer be able to report credit(s).
CPE Information
The American Society of Health-System Pharmacists is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.
ACPE #:
0204-000-19-419-H01-P
Release Date:
Tuesday, February 18, 2020
Expiration Date:
Wednesday, May 6, 2021
CE Credits:
1.5 hours/Application-based
Activity Fee:
Free of charge
CME Information
The American Society of Health-System Pharmacists is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
The American Society of Health-System Pharmacists designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
